Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 16, 2012

BARDA Contracts Tetraphase for Antibiotic Development with $11.5M Up Front

  • Tetraphase Pharmaceuticals has won a $67 million contract from BARDA for the development of TP-434, an antibiotic effective against multidrug-resistant gram-negative pathogens. The company will work on this project with CUBRC, a nonprofit organization that conducts R&D, testing, and systems integration programs in fields including medical sciences as well as chemical and biological defense. The contract includes a 12-month base period with committed funding of $11.5 million and subsequent option periods.

    The BARDA contract includes preclinical efficacy and toxicology studies, clinical trials, manufacturing activities, and associated regulatory activities to position the broad-spectrum antibiotic TP-434 as a potential empiric countermeasure for the treatment of inhalational disease caused by Bacillus anthracis, Francisella tularensis, and Yersinia pestis. In parallel, TP-434 is being developed as a potential therapeutic agent for serious hospital infections including those caused by multidrug-resistant aerobic and/or anaerobic gram-negative and gram-positive pathogens.

    TP-434's spectrum and pharmacokinetic properties are consistent with its use as a once-daily monotherapy, according to Tetraphase. Preliminary Phase I data have shown that TP-434 also has the potential to be developed as an oral therapy. TP-434 I.V. is currently in Phase II development for complicated intra-abdominal infections. 

    “BARDA’s award covering the development of TP-434 brings the total federal funding in support of the development of Tetraphase’s antibiotics to more than $100 million,” says Guy Macdonald, president and CEO of Tetraphase.

    In October 2011, Tetraphase was awarded a $36 million NIAID contract for the development of its respiratory disease antibiotic candidiate, TP-271. Under this agreement as well the firm will be working as a subcontractor to CUBRC. The NIAID award to Tetraphase includes $6 million in committed funding over an initial 25 months.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »